Clinical algorithms on cardiovascular risk factors in renal patients

Nephrology Dialysis Transplantation

Volumn 15, Issue SUPPL. 5, 2000, Pages 123-154

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRINOGEN; GEMFIBROZIL; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; IMIDAZOLINE RECEPTOR; LIPOPROTEIN A; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHORUS; POLYSULFONE; POTASSIUM; SODIUM; SODIUM CHLORIDE; STATIN; TRIACYLGLYCEROL; UNINDEXED DRUG; WATER; CARDIOVASCULAR AGENT;

ALGORITHM; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RISK; CLINICAL PROTOCOL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DIABETIC NEPHROPATHY; DIAGNOSTIC APPROACH ROUTE; DIET THERAPY; DYSLIPIDEMIA; HEART FAILURE; HEMODIALYSIS; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; LABORATORY TEST; MEDICAL DECISION MAKING; MICROALBUMINURIA; PERITONEAL DIALYSIS; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT INDICATION; TREATMENT PLANNING; ARTICLE; BLOOD; CARDIOVASCULAR DISEASE; HEART MUSCLE REVASCULARIZATION; KIDNEY FAILURE; PRACTICE GUIDELINE; RENAL REPLACEMENT THERAPY; RISK FACTOR;

ALGORITHMS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; HUMANS; KIDNEY FAILURE; MYOCARDIAL REVASCULARIZATION; RENAL DIALYSIS; RISK FACTORS;

EID: 0033782856     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (153)

1. Cardiac disease in dialysis patients: Diagnosis, burden of disease, prognosis, risk factors, and management
2. Controlling the epidemic of cardiovascular disease in chronic renal disease
3. Importance of homocysteine, lipoprotein (a), and non-classical cardiovascular risk factors (fibrinogen, and advanced glycation end products) for atherogenesis in uraemic patients
4. The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: A prospective follow-up
5. Lipoprotein(a) concentration and apolipoprotein(a) size: A synergistic role in advanced atherosclerosis?
6. Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease
7. Reversal of hyperhomocyst(e)inaemia in chronic renal failure-is folic or folinic acid the answer?
8. Importance of hyperlipidaemia and therapy in renal patients
9. Controlling the epidemic of cardiovascular disease in chronic renal disease
10. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults
11. Hyperlipidemia in patients with chronic renal disease
12. Prevention of coronary heart disease in clinical practice
13. High-flux dialysis membranes improve lipid profile in chronic hemodialysis patients
14. High flux dialysis membranes improve plasma lipoprotein profiles in patients with end-stage renal disease
15. Improvement of plasma lipoprotein profiles during high-flux dialysis
16. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
17. Hypertension in patients with chronic renal disease
18. The sixth report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure
19. Blood pressure control, proteinuria, and the progression of renal disease. The modification of diet in renal disease study
20. Clinical assessment of dry weight
21. Treatment of hypertension in dialysis patients by ultrafiltration: Role of cardiac dilatation and time factor
22. Dietary salt restriction and reduction of dialysate sodium to control hypertension in maintenance haemodialysis patients
23. Long, slow dialysis
24. In search of ideal hemodialysis: Is prolonged frequent dialysis the answer?
25. Fluid state and blood pressure control in patients treated with long and short haemodialysis
26. The effect of long, slow haemodialysis on patient survival
27. Daily home haemodialysis in the Netherlands: Effects on metabolic control, haemodynamics, and quality of life
28. Thermal balance and dialysis hypotension
29. Multicentre randomized study on the effect of thermal balance on vascular stability in hemodialysis (HD) patients
30. Convective treatments with on-line production of replacement fluid: A clinical experience lasting 6 years
31. Online monitoring in continuous renal replacement therapies
32. Sodium content in automated peritoneal dialysis solutions
33. Blood pressure control in dialysis patients: Importance of the lag phenomenon
34. Blood pressure control, proteinuria, and the progression of renal disease. The modification of diet in renal disease study
35. Achievement and safety of a low blood pressure goal in chronic renal disease. The modification of diet in renal disease study group
36. The sixth report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure
37. Coadministration of thiazides increases the efficacy of loop diuretics even in patients with advanced renal failure
38. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria
39. In chronic nephropathies prolonged ACE inhibition can induce remission: Dynamics of time-dependent changes in GFR. Investigators of the GISEN group
40. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: Is this a cause for concern?
41. Hypertension in chronic renal failure and end stage renal disease patients treated with haemodialysis or peritoneal dialysis
42. Cardiovascular risk in end-stage renal disease: Vascular aspects
43. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis
44. Nephrologists neglect administration of betablockers to dialysed diabetic patients
45. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
46. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction
47. Use of calcium channel blockers in hypertension
48. Anaphylactoid reactions during hemodialysis on AN69 membranes in patients receiving ACE inhibitors
49. Anaphylactoid reactions during hemodialysis
50. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT collaborative research group
51. Nephropathie und hypertonie bei diabetes mellitus
52. Mortality from coronary heart disease in subjects with type II diabetes and in non-diabetic subjects with and without prior myocardial infarction
53. Incidence of cardiovascular disease in type I (insulin dependent) diabetic subjects with and without diabetic nephropathy in Finland
54. Progression of renal failure in diabetic nephropathy
55. Diabetes and syndrome X:Focus on reduction of cardiovascular and renal events
56. Diabetic nephropathy: From micro- To macroalbuminuria
57. Microalbuminuria and coronary heart disease in NIDDM
58. Reversed circadian blood pressure is associated with occurences of both fatal and nonfatal vascular events in NIDDM subjects
59. 24-h ambulatory blood pressure and retinopathy in normoalbiminuric IDDM patients
60. Cigarette smoking as a risk factor for macroproteinuria and proliferative retinopathy in type I diabetes
61. Diabetes, other risk factors and 12-year cardiovascular mortality for men in the multiple risk factor intervention trial
62. Prevalence of and risk factors for, angiographically determined coronary artery disease in type I diabetic patients with nephropathy
63. Chronic renal insufficiency in hypertension: Slowing its progression
64. Effects of antihypertensive therapy on the kidney in patients with diabetes: A meta-regression analysis
65. The use of antihypertensive agents in prevention and treatment of diabetic nephropathy
66. Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: A systematic overview of randomized placebo-controlled trials
67. The sixth report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure
68. Diabetes and syndrome X: Focus on reduction of cardiovascular and renal events
69. Renal disease and hypertension in non-insulin-dependent diabetes mellitus
70. High incidence of silent myocardial ischemia in elderly patients with non insulin-dependent diabetes mellitus
71. Silent myocardial ischemia in patients with diabetes: Who to screen
72. Cardiovascular problems in diabetic patients on renal replacement therapy
73. Silent myocardial ischemia and microalbuminuria in asymptomatic subjects with non-insulin-dependent diabetes mellitus
74. Nephropathy in patients with type 2 diabetes mellitus
75. How far should blood pressure be reduced in diabetic hypertensive patients?
76. Diabetic nephropathy: From micro- To macroalbuminuria
77. The sixth report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure
78. The effect of metabolic control on development and progression of diabetic nephropathy
79. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus
80. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
81. Meta-analysis of effects of intensive blood glucose control on late complications of type I diabetes
82. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type II diabetes
83. Effect of intensive blood glucose control with metformin on complications in overweight patients with type II diabetes
84. Biguanide-associated lactic acidosis. Case report and review of the literature
85. Kidney function and age are both predictors of pharmacokinetics of metformin
86. Simultaneous pancreas-kidney transplantation reduces excess mortality in type 1 diabetic patients with end-stage renal disease
87. Effect of simultaneous pancreas kidney transplantation on mortality of patients with type-1 diabetes mellitus and end-stage renal failure
88. Simultaneous pancreas kidney transplantation and living related donor renal transplantation in patients with diabetes: Is there a difference in survival?
89. Mortality risks of peritoneal dialysis and hemodialysis
90. Ten years experience of renal replacement treatment in the elderly
91. Comparison of long-term survival between hemodialysis and peritoneal dialysis
92. Comparing mortality rates on CAPD/CCPD and hemodialysis. The canadian experience: Fact or fiction?
93. Cardiovascular problems in diabetic patients on renal replacement therapy
94. Preventing amputations in patients with end stage renal disease: Whatever happened to foot care?
95. Controlling the epidemic of cardiovascular disease in chronic renal disease
96. Cardiovascular risk in end-stage renal disease: Vascular aspects
97. Predialysis glycemic control is an independent predictor of clinical outcome in type II diabetics on continuous ambulatory peritoneal dialysis
98. Poor pre-dialysis glycaemic control is a predictor of mortality in type II diabetic patients on maintenance haemodialysis
99. Glucose homeostasis and the kidney
100. The effect of insulin delivery route on lipoproteins in type I diabetic patients on CAPD
101. Insulin therapy in uremic diabetic patients on continuous ambulatory peritoneal dialysis; comparison of intraperitoneal and subcutaneous administration
102. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction
103. Treatment of coronary artery disease in patients with renal failure
104. Controlling the epidemic of cardiovascular disease in chronic renal disease
105. Cardiac troponin T is elevated in asymptomatic patients with chronic renal failure
106. Cardiac troponin I, cardiac troponin T, and creatine kinase MB in dialysis patients without ischemic heart disease: Evidence of cardiac troponin T expression in skeletal muscle
107. Cardiac troponin I. A marker with high specificity for cardiac injury
108. Acute myocardial infarction in patients with end-stage renal disease
109. How to use ACE-inhibitors, beta-blockers, and newer therapies in AMI
110. Unfractionated and low-molecular-weight heparins in acute coronary syndromes: Current recommendations
111. Guidelines for the diagnosis and management of unstable angina and non-Q-wave myocardial infarction: Proposed revisions. International cardiology forum
112. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus
113. Lipid-lowering therapy for average lipid levels: The CARE trial
114. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
115. Cardiac disease in dialysis patients. Diagnosis, burden of disease, prognosis, risk factors, and management
116. Diagnosis and management of coronary artery disease in patients with end-stage renal disease on hemodialysis
117. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: A report of the american college of cardiology/American heart association task force on practice guidelines
118. Screening diabetic transplant candidates for coronary artery disease: Identification of a low risk subgroup
119. Incidence and long-term significance of transient ST segment deviation in hemodialysis patients
120. Controlling the epidemic of cardiovascular disease in chronic renal disease
121. Treatment of coronary artery disease in patients with renal failure
122. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin
123. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
124. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
125. Cardiac disease in dialysis patients: Diagnosis, burden of disease, prognosis, risk factors, and management
126. Outcome and risk factors for left ventricular disorders in chronic uraemia
127. Arterial blood pressure and left ventricular hypertrophy in haemodialysis patients
128. Left ventricular mass increase in early renal disease: Impact of decline in hemoglobin
129. Risk factors for the development of left ventricular hypertrophy in a prospectively followed cohort of dialysis patients
130. Contributive factors to cardiovascular hypertrophy in renal failure
131. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease
132. Therapy of heart failure
133. Treatment of cardiac insufficiency: Does treatment depend on whether its cause is ischemic or idiopathic
134. Production of C-reactive protein and risk of coronary events in stable and unstable angina
135. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
136. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
137. C-reactive protein as an outcome predictor for maintenance hemodialysis patients
138. Acute-phase inflammatory process contributes to malnutrition, anemia, and possibly other abnormalities in dialysis patients
139. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure
140. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients
141. C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients
142. Serum C-reactive protein (CRP) and risk of death in chronic dialysis patients
143. Chronic infections and coronary heart disease: Is there a link?
144. Should ultra-pure dialysate be mandatory?
145. European Pharmacopoeia: Haemodialysis solutions, concentrates, water for diluting
146. Swedish Pharmacopoeia: Preparation and handling of solutions for haemodialysis
147. Effects of dialyser and dialysate on the acute phase reaction in clinical bicarbonate dialysis
148. Effect of the hemodialysis membrane on the inflammatory reaction in vivo
149. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients
150. Long-term effects of pravastatin on plasma concentration of C-reactive protein